跳到正文
原文
HHS· @HHSGov · X·· 23 天前AI 评分22
AI 导读

美国国家癌症研究所资助的研究显示,许多早期、HR+/HER2-乳腺癌女性患者可仅接受激素治疗。21基因检测有助于指导这一决策,在化疗不太可能获益时,使患者免于化疗副作用。#BCAM 了解更多👉 https://www.cancer.gov/news-events/press-releases/2018/tailorx-breast-cancer-chemotherapy

正文

National Cancer Institute-funded research showed many women with early-stage, HR+/HER2- breast cancer can be treated with hormone therapy alone. A 21-gene test helps guide the decision, sparing patients chemo’s side effects when it’s unlikely to help. #BCAM

Learn more👉 https://www.cancer.gov/news-events/press-releases/2018/tailorx-breast-cancer-chemotherapy

来源:HHS · x.com